Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical Inc. Class A

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Globus Medical on May 8 and set a price target of $95.00. The company’s shares c...

Stifel Nicolaus Reaffirms Their Hold Rating on Globus Medical (GMED)

Globus Medical (($GMED)) has held its Q1 earnings call. Read on for the main highlights of the call. Globus Medical’s latest earnings call struck a...

Globus Medical Earnings Call Signals Profitable Momentum

Piper Sandler Sticks to Their Buy Rating for Globus Medical (GMED)

Canaccord Genuity analyst Caitlin Cronin reiterated a Buy rating on Globus Medical today and set a price target of $115.00. According to TipRanks, ...

Market Cap	$11.98B	P/E Ratio	17.95
52W High	$101.40	52W Low	$51.79
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	28.2%	52W Position	67.1%
Overall Score	66	Value Score	80
Quality Score	73	Technical Score	45

EPS Current Est	$4.74	EPS Next Est	$5.06
EPS Growth Est	+6.8%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMED	$85.10	+0.34%	1.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMED	$85.10	+0.3%	1.88M
3
4
5
6

GMED

GMED

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Globus Medical Inc. Class A Data in Excel

Get Globus Medical Inc. Class A Data in Excel